PIM
MYGN icon

Provident Investment Management’s Myriad Genetics MYGN Stock Holding History

Provident Investment Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-375,482
Closed -$12.8M – 54
2015
Q2 		$12.8M Buy
375,482
+450
+0.1% +$15.3K 2.53% 20
2015
Q1 		$13.3M Buy
375,032
+7,055
+2% +$253K 2.7% 18
2014
Q4 		$12.5M Buy
367,977
+5,912
+2% +$210K 2.73% 19
2014
Q3 		$14M Buy
362,065
+2,050
+0.6% +$76.5K 3.25% 17
2014
Q2 		$14M Buy
+360,015
New +$13.4M 3.31% 18

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Provident Investment Management's MYGN Position: Q3 2015 in Review

Provident Investment Management sold out of Myriad Genetics (MYGN) in Q3 2015, closing a stake of 375,482 shares — an estimated $12.8M sold.

Provident Investment Management first reported a position in MYGN in Q2 2014 and held it in 5 quarters. The position peaked at $14M in Q2 2014. 234 funds tracked by Wall St. Rank hold MYGN as of Q3 2015.

  • Provident Investment Management reported no remaining Myriad Genetics position as of Q3 2015 after selling out during the quarter.
  • Provident Investment Management sold 375,482 Myriad Genetics shares in Q3 2015, an estimated $12.8M.
  • Provident Investment Management first reported a position in Myriad Genetics in Q2 2014 and held it in 5 quarters.
  • Provident Investment Management's Myriad Genetics position peaked at $14M in Q2 2014.
  • 234 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2015.

Based on Provident Investment Management's 13F filing for Q3 2015, filed 9 Nov 2015.